Wellington Management Group LLP Has $57.99 Million Holdings in Insmed, Inc. $INSM

Wellington Management Group LLP increased its position in shares of Insmed, Inc. (NASDAQ:INSM) by 36.3% in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 543,893 shares of the biopharmaceutical company’s stock after buying an additional 144,849 shares during the quarter. Wellington Management Group LLP’s holdings in Insmed were worth $57,990,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of INSM. iA Global Asset Management Inc. grew its stake in Insmed by 15,973.5% in the 4th quarter. iA Global Asset Management Inc. now owns 26,682 shares of the biopharmaceutical company’s stock valued at $4,644,000 after buying an additional 26,516 shares during the last quarter. Monashee Investment Management LLC acquired a new stake in Insmed during the fourth quarter worth approximately $8,702,000. SBI Okasan Asset Management Co.Ltd. bought a new stake in shares of Insmed during the fourth quarter worth approximately $3,562,000. Hsbc Holdings PLC boosted its holdings in shares of Insmed by 8,052.6% during the fourth quarter. Hsbc Holdings PLC now owns 123,267 shares of the biopharmaceutical company’s stock worth $21,493,000 after acquiring an additional 121,755 shares during the period. Finally, Empowered Funds LLC grew its position in shares of Insmed by 32.6% in the first quarter. Empowered Funds LLC now owns 51,986 shares of the biopharmaceutical company’s stock valued at $8,501,000 after purchasing an additional 12,775 shares during the last quarter.

Analysts Set New Price Targets

INSM has been the topic of a number of recent research reports. Guggenheim lowered their target price on Insmed from $207.00 to $205.00 and set a “buy” rating on the stock in a research note on Friday, August 7th. Mizuho set a $192.00 price objective on Insmed in a report on Tuesday, June 16th. BMO Capital Markets assumed coverage on Insmed in a research report on Monday, July 20th. They set an “outperform” rating and a $192.00 price objective on the stock. Evercore reissued an “outperform” rating and set a $170.00 target price on shares of Insmed in a report on Friday, August 7th. Finally, Wells Fargo & Company upped their price target on shares of Insmed from $161.00 to $169.00 and gave the company an “overweight” rating in a research note on Friday, August 7th. Two research analysts have rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $205.52.

Insmed Stock Performance

Shares of Insmed stock opened at $126.68 on Friday. The company has a current ratio of 3.72, a quick ratio of 3.40 and a debt-to-equity ratio of 0.74. The company has a market cap of $27.66 billion, a PE ratio of -30.82 and a beta of 0.82. The company has a 50 day moving average of $115.40 and a 200-day moving average of $125.21. Insmed, Inc. has a 1-year low of $90.39 and a 1-year high of $212.75.

Insmed (NASDAQ:INSM) last announced its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.67) by $0.61. The business had revenue of $425.49 million during the quarter, compared to the consensus estimate of $395.50 million. Insmed had a negative net margin of 76.94% and a negative return on equity of 123.94%. The company’s revenue was up 296.1% on a year-over-year basis. During the same period in the previous year, the business earned ($1.70) earnings per share. As a group, equities research analysts forecast that Insmed, Inc. will post -1.83 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CEO William Lewis sold 10,699 shares of the company’s stock in a transaction on Thursday, July 9th. The stock was sold at an average price of $117.40, for a total transaction of $1,256,062.60. Following the completion of the sale, the chief executive officer directly owned 259,058 shares in the company, valued at $30,413,409.20. This represents a 3.97% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Roger Adsett sold 239,850 shares of Insmed stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $133.27, for a total value of $31,964,809.50. Following the completion of the transaction, the chief operating officer owned 98,744 shares in the company, valued at approximately $13,159,612.88. This represents a 70.84% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 273,753 shares of company stock worth $35,604,764 in the last ninety days. 2.10% of the stock is owned by insiders.

About Insmed

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.